Opsens (TSE:OPS)‘s stock had its “outperform” rating reissued by investment analysts at Raymond James in a research report issued on Thursday, Stock Target Advisor reports. They presently have a C$6.00 price target on the stock. Raymond James’ price target indicates a potential upside of 92.93% from the stock’s current price.
A number of other equities research analysts have also commented on OPS. Royal Bank of Canada restated a “buy” rating and set a C$3.50 price objective on shares of Opsens in a research report on Tuesday, September 21st. M Partners set a C$2.25 price target on Opsens in a research note on Wednesday, July 14th.
Shares of TSE:OPS traded up C$0.16 during midday trading on Thursday, reaching C$3.11. The company had a trading volume of 95,287 shares, compared to its average volume of 169,413. The company has a debt-to-equity ratio of 29.99, a quick ratio of 5.85 and a current ratio of 6.75. Opsens has a 1-year low of C$0.68 and a 1-year high of C$3.50. The firm has a market cap of C$332.20 million and a price-to-earnings ratio of 444.29. The company has a fifty day simple moving average of C$2.74 and a two-hundred day simple moving average of C$2.31.
Opsens Inc develops, manufactures, installs, and sells fiber optic sensors for interventional cardiology, fractional flow reserve (FFR), oil and gas, and industrial applications. The company operates in two segments, Medical and Industrial. The Medical segment primarily focuses on physiological measurement, such as FFR and dPR in the coronary artery stenosis market; and supplies a range of miniature optical sensors to measure pressure and temperature used in integrated applications in other medical devices, as well as licenses its optical sensor technology.
Featured Story: What is the S&P/ASX 200 Index?
Receive News & Ratings for Opsens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opsens and related companies with MarketBeat.com's FREE daily email newsletter.